BioEclipse Therapeutics

BioEclipse Therapeutics

Early Stage

Clinical-stage immunotherapy

Clinical-stage immunotherapy


Raised to Date: Raised: $0

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common



SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Not Funded
Reporting Date


Days Remaining
Not Funded
% of Min. Goal
Not Funded
% of Max. Goal
Not Funded
Likelihood of Max
Not Funded
Avg. Daily Raise


Not Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Mountain View, California

Business Type


BioEclipse Therapeutics, with a valuation of $28.99 million, is raising funds on NetCapital. It is an immunotherapy company using its proprietary technology platform to combine the power of an oncolytic virus with the tumor-locating ability of CIK cells. The technology helps BioEclipse Therapeutics in developing the next generation of immuno-oncology therapeutics. BioEclipse Therapeutics is led by an experienced team and has CRX100 clinical trials underway. Pamela Contag founded BioEclipse Therapeutics in May 2006. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,069,998. The campaign proceeds will be used for compensation, rent, research, and lab supplies.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 01/19/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
BioEclipse Therapeutics on NetCapital 2022
Platform: Netcapital
Security Type: Equity - Common
Valuation: $28,993,373
Price per Share: $2.55

Follow company

Follow BioEclipse Therapeutics on NetCapital 2022

Buy BioEclipse Therapeutics's Deal Report

Warning: according to the close date for this deal, BioEclipse Therapeutics may no longer be accepting investments.

BioEclipse Therapeutics Deal Report

Get KingsCrowd’s comprehensive report on BioEclipse Therapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether BioEclipse Therapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the BioEclipse Therapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge